Alnylam Pharmaceuticals, Inc. (ALNY) announced that the U.S. Food & Drug Administration, or FDA, has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy, or FAP, one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis, or ATTR.
Saraswathy Nochur, vice president, Regulatory Affairs and Quality Assurance at Alnylam, stated, "We believe RNAi therapeutics represent a novel and exciting approach for ATTR patients and have great potential to make a meaningful impact in the treatment of this devastating disease. We look forward to sharing Phase I clinical data from our ALN-TTR02 program early in the third quarter, and, assuming continued positive results, we plan to advance to a pivotal trial in 2013. Alnylam is committed to bringing this high impact medicine to patients afflicted with ATTR."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.